D. Boral Capital Reaffirms “Buy” Rating for Hoth Therapeutics (NASDAQ:HOTH)

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They presently have a $5.00 target price on the stock. D. Boral Capital’s price target suggests a potential upside of 338.60% from the stock’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics in a research note on Thursday, January 23rd.

Hoth Therapeutics Trading Down 8.1 %

HOTH opened at $1.14 on Tuesday. Hoth Therapeutics has a 12 month low of $0.58 and a 12 month high of $3.80. The business’s 50-day moving average price is $1.20 and its 200-day moving average price is $0.98. The company has a market cap of $7.87 million, a P/E ratio of -0.86 and a beta of 0.84.

Hedge Funds Weigh In On Hoth Therapeutics

An institutional investor recently raised its position in Hoth Therapeutics stock. Geode Capital Management LLC increased its holdings in Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 95,946 shares of the company’s stock after purchasing an additional 13,038 shares during the quarter. Geode Capital Management LLC owned approximately 1.39% of Hoth Therapeutics worth $72,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 7.08% of the stock is currently owned by hedge funds and other institutional investors.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.